Trial · NCT03783949
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival | 3 years 10 months | Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions |
| Secondary | Progression-free Survival in BRCA Mutated Patients | 3 years 10 months | Progression-free survival analysis in BRCA mutated patients |
| Secondary | Post-progression PFS (PFS2) | 3 years 10 months | Post-progression PFS (PFS2) analysis |
| Secondary | Time to First Subsequent Therapy (TFST) | 3 years 10 months | Time to First Subsequent Therapy (TFST) analysis |
| Secondary | Time to Second Subsequent Therapy (TSST) | 3 years 10 months | Time to Second Subsequent Therapy (TSST) analysis |
| Secondary | Progression-free Survival in Patients Without BRCA Mutation or With Unknown BRCA Status | 3 years 10 months | Progression-free Survival analysis in Patients without BRCA mutation or with unknown BRCA status |
| Secondary | Objective Response Rate (ORR) | 3 years 10 months | Objective response rate (ORR) analysis |
| Secondary | Overall Survival (OS) | 3 years 10 months | Overall survival (OS) analysis |
| Secondary | Progression-free Survival in Patients With Prior PARPi Treatment | 3 years 10 months | Progression-free Survival analysis in Patients with prior PARPi treatment |
| Secondary | Progression-free Survival in Patients With One Prior Line of Therapy | 3 years 10 months | Progression-free Survival analysis in Patients with one prior line of therapy |
| Secondary | Progression-free Survival in Patients With More Then One Prior Line of Therapy | 3 years 10 months | Progression-free Survival analysis in Patients with more then one prior line of therapy |
| Secondary | Progression-free Survival in Patients Without Prior PARPi Treatment | 3 years 10 months | Progression-free Survival analysis in Patients without prior PARPi treatment |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03783949/registered